You are currently viewing Manchester Institute of Biotechnology celebrates 20 years of research and innovation

Among its success stories is work inspired by Joy Milne, who noticed a distinctive odour associated with Parkinson’s disease. Researchers developed a skin-swab approach to study chemical differences in sebum, using mass spectrometry. The research has involved more than 7,000 participants and is informing development of a potential non-invasive test that could detect the disease seven years before symptoms appear.

In research supported by the Gates Foundation, MIB scientists are developing low-cost biomanufacturing routes to key Global Health drugs, to make these therapeutics more accessible to the global population. In recent work, the team have developed new biocatalytic methods to efficiently produce lenacapavir, a highly effective, long-acting HIV-prevention medicine whose manufacturing cost remains a barrier to wider access. The team has engineered enzymes that can efficiently produce a key component of the drug and is now exploring whether AI could offer a faster way to design the enzymes needed for its manufacture.

From research to industry

MIB’s impact also extends beyond individual research discoveries. The Institute has helped develop skills, businesses and industrial capability around biotechnology, supporting researchers to move ideas from the laboratory towards commercial and industrial applications.

One example is the Centre of Excellence for Biocatalysis, Biotransformations and Biocatalytic Manufacture (CoEBio3), which combined research with industry-focused training and helped establish Manchester as a major centre for industrial biocatalysis. Its researchers have commercialised more than 1,000 biocatalysts, with enzymes used at industrial scale and technologies developed with international pharmaceutical companies.

That expertise has also helped create new businesses. MIB spin-out C3 Biotech, for example, is developing ways to manufacture chemicals from low-value waste rather than fossil-derived raw materials. At its pilot plant in Stockport, the company has demonstrated continuous production for more than six months, producing more than 100kg of an intermediate that can be converted into the acrylic material PMMA.

Building the next generation

As MIB enters its third decade, it is investing in the people, skills and partnerships that will shape the future of biotechnology, from training the next generation of researchers to supporting businesses and creating new companies.

The Manchester Biomolecule Engineering Centre (MBEC) provides hands-on training in technologies spanning molecular design, laboratory automation, analytical characterisation and structural biology. Researchers and industry professionals can work alongside specialists before taking the techniques and expertise back to their own laboratories.

Manchester is also involved in three doctoral programmes that will train more than 90 researchers across biocatalysis, AI-enabled biotechnology and microbial engineering.

“The University of Manchester is a public research university in Manchester, England. The main campus is south of Manchester City Centre on Oxford Road.”

Please visit the firm link to site


Corporate, Tax, Legal, Wealth Management by Totalserve
Cloud, Data, Colocation, Cybersecurity by CL8
Audit, Accounting, Payroll by PGE&Co

Contribute and send us your Article.


Interested in more? Learn below.